$RGBP

REGEN BIOPHARMA INC

Pharmaceutical preparations · OTCID

0.000 +100.00% as of 11/4/2026, 2:01:54 PM · delayed

Sentiment

BULLISH BEARISH

No open positions yet.

No threads yet for $RGBP. Be the first to post.

Official links

Filings

8-K Mon Nov 02 2026 00:00:00 GMT-0500 (Eastern Standard Time) SEC.gov View
10-Q Mon Aug 17 2026 00:00:00 GMT-0400 (Eastern Daylight Time) SEC.gov View
NT 10-Q Thu Aug 13 2026 00:00:00 GMT-0400 (Eastern Daylight Time) SEC.gov
8-K Wed Jul 15 2026 00:00:00 GMT-0400 (Eastern Daylight Time) SEC.gov View
10-Q Thu May 14 2026 00:00:00 GMT-0400 (Eastern Daylight Time) SEC.gov View
8-K Wed Mar 04 2026 00:00:00 GMT-0500 (Eastern Standard Time) SEC.gov View
10-Q Fri Feb 13 2026 00:00:00 GMT-0500 (Eastern Standard Time) SEC.gov View
8-K Mon Feb 02 2026 00:00:00 GMT-0500 (Eastern Standard Time) SEC.gov View

All filings

Timeline

filing 11/1/2026 8-K filed
revenue 9/8/2026 Revenue reported: $236.6K, year ended Sep 30, 2025
revenue 9/8/2026 Revenue reported: $236.6K, year ended Sep 30, 2024
revenue 9/8/2026 Revenue reported: $236.6K, year ended Sep 30, 2023
revenue 9/8/2026 Revenue reported: $59.1K, quarter ended Jun 30, 2026
revenue 9/8/2026 Revenue reported: $59.1K, quarter ended Mar 31, 2026
revenue 9/8/2026 Revenue reported: $59.1K, quarter ended Dec 31, 2025
revenue 9/8/2026 Revenue reported: $59.4K, quarter ended Sep 30, 2025 (derived)
revenue 9/8/2026 Revenue reported: $59.1K, quarter ended Jun 30, 2025
revenue 9/8/2026 Revenue reported: $59.1K, quarter ended Mar 31, 2025

Company reliability

–

No resolved statements yet.

Revenue

Quarterly

Jun 2026 $59K
Mar 2026 $59K
Dec 2025 $59K
Sep 2025 $59K derived

Annual

FY 2025 $237K
FY 2024 $237K
FY 2023 $237K

Source: SEC XBRL

CEO compensation

$180K/yr (from $15K/month) (FY 2018)

Mr. David Koos (current CEO) - $360K total disclosed since 2016

Mr. David Koos

10-K

Provisional - extracted from filings, not verified.

Latest disclosed; no newer filing found.

FY 2016 $180K/yr extracted

Notes & debt

Provisional - extracted from filings, not verified.

IN DEFAULT · $930K in arrears
$200K matured May 5, 2020 10% 10-Q · 2026-08-17

Quote

On May 5, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $200,000 for consideration consisting of $200,000 cash.
$100K matured Dec 20, 2020 8% 10-Q · 2026-08-17

Quote

On December 20, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash.
$250K matured Jun 30, 2026 10% 10-Q · 2026-08-17

Quote

Effective September 4, 2024 the Company entered into a securities purchase agreement (the “Purchase Agreement”) with Coventry Enterprises, LLC (“Coventry”), pursuant to which Coventry Enterprises purchased a 10 % unsecured promissory Note (the “Note”) from the Company in the principal amount of $ 250,000 for consideration of $ 200,000 .
$50K matured Jun 30, 2026 8% 10-Q · 2026-08-17

Quote

On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 50,000 for consideration consisting of $ 50,000 cash.
$100K matured Jun 30, 2026 8% 10-Q · 2026-08-17

Quote

On March 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $ 100,000 for consideration consisting of $ 100,000 cash.
$130K matured Jul 28, 2026 10-Q · 2026-08-17

Quote

Item 3.02 Recent Sales of Unregistered Securities On July 28, 2925 Regen Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with CFI Capital LLC (“CFI”), pursuant to which CFI purchased a 6% convertible promissory Note (the “Note”) from the Company in the principal amount of $130,000 of which $13,000 was retained by CFI through an Original Issue Discount.
$100K matured Aug 5, 2026 10-Q · 2026-08-17

Quote

Item 3.02 Recent Sales of Unregistered Securities On August 5, 2025 Regen Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Labrys Fund II LP(“Labrys “), pursuant to which Labrys purchased a 6% convertible promissory Note (the “Note”) from the Company in the principal amount of $100,000 of which $15,000 was retained by Labrys through an Original Issue Discount.
OTHER ISSUANCES
$1K — 10-Q · 2026-08-17

Quote

On July 15, 2026, the Company issued 67,788,833 Common Shares in satisfaction of $ 2,900 of principal convertible indebtedness, $ 167 of accrued interest on principal convertible indebtedness and $ 1,000 of fees incurred pursuant to terms and conditions of convertible notes issued by the Company.
$1K — 10-Q · 2026-08-17

Quote

On July 13, 2026, the Company issued 64,248,333 Common Shares in satisfaction of $ 2,700 of principal convertible indebtedness, $ 155 of accrued interest on principal convertible indebtedness and $ 1,000 of fees incurred pursuant to terms and conditions of convertible notes issued by the Company.
$1K — 10-Q · 2026-08-17

Quote

On July 9, 2026, the Company issued 60,696,333 Common Shares in satisfaction of $ 2,500 of principal convertible indebtedness, $ 142 of accrued interest on principal convertible indebtedness and $ 1,000 of fees incurred pursuant to terms and conditions of convertible notes issued by the Company.
$1K — 10-Q · 2026-08-17

Quote

On July 7, 2026, the Company issued 57,161,333 Common Shares in satisfaction of $ 2,300 of principal convertible indebtedness, $ 130 of accrued interest on principal convertible indebtedness and $ 1,000 of fees incurred pursuant to terms and conditions of convertible notes issued by the Company.
$1K — 10-Q · 2026-08-17

Quote

On July 6, 2026, the Company issued 55,394,667 Common Shares in satisfaction of $ 2,200 of principal convertible indebtedness, $ 124 of accrued interest on principal convertible indebtedness and $ 1,000 of fees incurred pursuant to terms and conditions of convertible notes issued by the Company.
$31K — 10-Q · 2026-08-17

Quote

During the nine months ended June 30, 2026 the Company issued 116,465,570 Common Shares in satisfaction of $ 30,500 of fees incurred pursuant to terms and conditions of convertible notes issued by the Company.
$10K — 10-Q · 2026-08-17

Quote

During the quarter ended June 30, 2026 the Company issued 79,722,604 Common Shares in satisfaction of $10,000 of fees incurred pursuant to terms and conditions of convertible notes issued by the Company.
$125K — 10% 8-K · 2026-11-02

Quote

On October 27, 2026 Regen Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Coventry Enterprises, LLC (“Coventry”), pursuant to which Coventry Enterprises purchased a 10% unsecured promissory Note (the “Note”) from the Company in the principal amount of $125,000 of which $12,500 was retained by Coventry through an Original Issue Discount.
— — 8-K · 2026-11-02

Quote

Item 9.01 Financial Statements and Exhibits 10.1 Securities Purchase Agreement 10.2 Convertible Note 10.3 Equity Line 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
$60K — 10-Q · 2026-08-17

Quote

The increase in Accrued Interest is attributable to interest accrued but unpaid during the period ended june 30, 2026 on Notes Payable and Convertible Notes Payable.
$2.1M — 10-Q · 2026-08-17

Quote

As of June 30, 2026 and September 30, 2025 the following table represents the Company’s fair value hierarchy for items that are required to be measured at fair value on a recurring basis: SCHEDULE OF FAIR VALUE HIERARCHY MEASURED AT RECURRING BASIS June 30, 2026 Level 1 Level 2 Level 3 Derivative Liability - - $ 1,901,963 September 30, 2025 Level 1 Level 2 Level 3 Derivative Liability - - $ 2,079,618 Derivative Liability The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging.
No notes match this filter.

Top predictors

No resolved predictions on $RGBP yet.

Upcoming resolutions

Nothing awaiting resolution.